Emerging evidence suggests cyclin-dependent kinase 4/6 (CDK4/6) inhibitors as an attractive therapeutic strategy for solid cancers, and here, we summarize the current knowledge and exploration of their therapeutic potential in the most common pancreatobilliary cancers, cholangiocarcinoma and pancreatic ductal adenocarcinoma. This evidence concerns the gene CDK4 and cholangiocarcinoma.